Global Nasopharyngeal Cancer Market Trends, Size, Competitive Analysis and Forecast - 2018-2023

Nasopharyngeal cancer market is expected to grow at a significant rate during the forecast period 2018-2023. The nasopharynx is the upper part of the throat (pharynx) that lies behind the nose. The nasopharynx cancer or nasopharyngeal carcinoma (NPC) results from abnormal growth of cells in the nasopharynx. It is one of the rare cancer forms globally, ranking as the 27th most frequently diagnosed cancer globally in 2015. The market is expected to show a lucrative market growth rate. Increasing incidence of nasopharyngeal cancer across the globe high tobacco and alcohol consumption are the major factor driving the market during the forecasted period. As per the American Medical Association, the global incident cases of nasopharyngeal cancer in 2015 were more than 123,000 with a growth of 16.5% as compared to 2005. The prevalence of the cancer is in both male and female however male has more prevalence rate. There were 88,000 cases among men in 2015 with an incidence rate of 2.6 per 100,000 whereas it was 35,000 in women with an incidence rate of 0.9 per 100,000. Death rate per 100,000 were 1.4 in men and 0.5 in female. Furthermore, high intake of salt-preserved food and exposure to Epstein-Barr Virus (EBV) are also motivating the market. Almost all people infected with NPC have an infection by EBV virus in their blood. Infection with EBV is very common globally, often occurring in childhood. However, as per the American Cancer Society, the link between EBV infection and NPC is complex and it is not completely understood.

Request a free sample of our report on Global Nasopharyngeal Cancer Market: https://www.omrglobal.com/request-sample/nasopharyngeal-cancer-market

There are certain factors that are hindering the growth of the market. The high cost of treatment, low awareness toward cancer and an adverse side effect of treatment are the major restraint of the market. Alcohol and Tabaco consumption are the major cause for NPC however as per American Society of Clinical Oncology about 70% of Americans didn’t know that drinking alcohol is a risk factor for cancer. As per the National Center for Biotechnology Information, the cost of treatment of NPC range from $15,000 to $18,000.

A full report of Global Nasopharyngeal Cancer Market Is available at https://www.omrglobal.com/industry-reports/nasopharyngeal-cancer-market

Global Nasopharyngeal Cancer Market Segmentation

By Cancer Type
• Keratinising Squamous Cell Carcinoma
• Non-Keratinising Squamous Cell Carcinoma
• Undifferentiated Carcinomas
• Other (Adenocarcinoma and Adenoid Cystic Carcinomas)

By Diagnosis Method
• Initial Diagnosis
o Nasendoscopy
o Panendoscopy
o Fine Needle Aspiration/Needle Biopsy
• Advanced Diagnosis
o CT Scan
o PET Scan
o MRI Scan
o Bone Scan

By Therapy
• Chemotherapy
• Immunotherapy
• Surgery
• Targeted Therapy

Competitive Landscape
• Key Strategies
• Key Company Analysis

Regional Analysis
• North American
o United States
o Canada
• Europe
o UK
o Germany
o Spain
o France
o Italy
• APAC
o India
o China
o Japan
o Rest of APAC
• Rest of The World

Company Profiles
• Biodiem Ltd.
• Bristol-Myers Squibb
• Cyclacel Pharmaceuticals Inc.
• Eli Lilly And Co.
• GlaxoSmithKline Plc.
• Merck & Co., Inc.
• Novartis International AG
• Ono Pharmaceutical Co.,
• Safoni
• Theravectys SA

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/nasopharyngeal-cancer-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

About Us:
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting, and other research-based services.

For More Information, Visit https://www.omrglobal.com/

This release was published on openPR.